NCT06983951View on ClinicalTrials.gov

Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Light Chain Amyloidosis
Interventions
GENETIC

BCMA CART

"The cell product used in this study is a targeted BCMA autologous CART cell injection.~Research drug name: Targeted BCMA Autologous CART Cell Injection Drug code: BJBR-BCMA-006 Administration method: single intravenous injection"

Trial Locations (1)

100070

RECRUITING

Beijing Gobroad Brond Hospital, Beijing

All Listed Sponsors
lead

Beijing Boren Hospital

OTHER